Class Effect “Moratorium” Proposed By Harvard’s Avorn; FDA Should “Grow Up”
Executive Summary
FDA should be less reliant on potential class similarities in evaluating safety and efficacy, pharmacoepidemiologist Jerry Avorn (Harvard University) said
You may also be interested in...
Drug Similarities Provide Evidence Latitude, Temple Says; Diovan Example?
Pharmacologic similarity between compounds gives FDA greater latitude in the amount and type of data required for approval, Office of Medical Policy Director Robert Temple indicated during an Aug. 3 interview with "The Pink Sheet.
FDA Broadens Diovan Heart Failure Indication Based On Atacand Clinical Data
FDA has cleared Novartis' angiotensin II receptor blocker Diovan (valsartan) for first-line use in the treatment of heart failure using data generated by AstraZeneca for its ARB Atacand (candesartan)
Celebrex, NSAID Labeling Must Include Skin Reactions Warning, FDA Says
FDA is requiring labeling for non-steroidal anti-inflammatory drugs include a warning on skin reactions, in addition to a boxed warning on cardiovascular and gastrointestinal risk